Safety and Efficacy of Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata
Phase: PHASE2
Conditions: Alopecia Areata
Sponsor: University of Minnesota

( 
vt1  
Department of Dermatology 
University of Minnesota 

 -.. () --- )-CH S-
Title of Study 
Safety and Efficacy of Combined Restylane® and Triamcinolone 
Acetonide 10 mg/cc lntralesional Injections for the Treatment of 
Alopecia Areata 
Purpose 
The purpose of this pilot research study is to determine the safety and 
efficacy of combined hyaluronic acid, Restylane®, and intralesional 
Triamcinolone acetonide 10 mg/cc in the management of alopecia 
areata. Dermal injections of Restylane® and triamcinolone acetonide 10 
mg/cc will be performed at areas of hair loss on study participants. 
Background 
AA is an autoimmune organ specific T-cell mediated disease which 
targets hair follicles and causes non-scarring hair loss5• Hairs that are 
shed are either in telogen or dystrophic anagen6• AA can present as 
patches of alopecia on the scalp, complete loss of hair on the scalp 
(AA total is) or loss of hair from the entire body (AA universal is) 1.
This fairly common disorder can affect patients of all ages8• Lifetime risk 
has been estimated to be 1.7%. A significant number of these cases, 
approximately 7%, may eventually evolve into chronic and severe hair 
loss8• Because the pathogenesis of the disease and the factors 
contributing to development are not fully understood, predicting the 
course of the disease is extremely difficult1. The psychological affects 
on patients with AA can be devastating. Increased risk of psychiatric 
disorders such as anxiety disorders (39%) and major depression (39%) 
have been found in patients affected by the disease3•
With regards to the management of AA, use of IL corticosteroids has 
become a first line therapy. Synthetic corticosteroids are utilized in 
Version 04/03/2013 
Restylane-Alopecia Areata study 
1 
NCT01797432